Autolus Therapeutics (AUTL) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

AUTL Autolus Therapeutics

Watchlist

3.320
+0.050+1.53%

Close Nov 29 13:00 ET

3.340
+0.020+0.60%

Post 17:02 ET

883.52MMarket Cap-2721P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Is Autolus Therapeutics (NASDAQ:AUTL) Using Too Much Debt?
Simply Wall StNov 29 06:52 ET
European Equities Traded in the US as American Depositary Decline in Tuesday Trading
MT NewswiresNov 26 11:12 ET
Goldman Sachs Upgrades Autolus Therapeutics(AUTL.US) to Buy Rating, Raises Target Price to $7.6
Moomoo NewsNov 19 03:36 ET · Ratings
Autolus Therapeutics Analyst Ratings
BenzingaNov 18 08:03 ET · Ratings
Goldman Sachs Upgrades Autolus Therapeutics to Buy From Neutral, Adjusts Price Target to $7.60 From $7
MT NewswiresNov 18 07:51 ET · Ratings
Autolus Therapeutics: FDA Approval of Aucatzyl De-Risks Platform, Significant Upside Anticipated
TipRanksNov 18 06:16 ET

Comments

stderr

Nov 12 12:21

$Autolus Therapeutics (AUTL.US)$ Nothing happened?

Momomimk

Nov 11 03:23

$Autolus Therapeutics (AUTL.US)$

Share Your Profit/Loss

Jaguar8

Nov 8 16:37

FDA approval. On my Monday, watchlist too

$Autolus Therapeutics (AUTL.US)$

This_Guy

Nov 8 16:31

$Autolus Therapeutics (AUTL.US)$
ya I'm getting in here

Jaguar8

Nov 8 15:41

NEWS

$Autolus Therapeutics (AUTL.US)$
Autolus Therapeutics Announces FDA Approval of AUCATZYL® (obecabtagene autoleucel – obe-cel) for adults with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)
• AUCATZYL is the first CAR T therapy approved by the FDA with no requirement for a REMS program (Risk Evaluation Mitigation Strategy)
• Approval based on FELIX clinical trial of obe-cel in adult patients with r/r B-ALL
• Conference call to be held on November 11 at 08:30 am EST/13:3...

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall

No Data

AUTL Autolus Therapeutics

Trade Overview

Capital Trend

News

Comments

Analysis

Analyst Rating

Price Target